A first-in-human trial of the integrin beta-6-targeted antibody-drug conjugate, SGN-B6A, in patients with advanced solid tumors

被引：1

作者：

Calvo, E. ^{[1
]}

Hollebecque, A. ^{[2
]}

Dowlati, A. ^{[3
]}

Piha-Paul, S. A. ^{[4
]}

Galvao, V. ^{[5
]}

Lopez, J. ^{[6
]}

Sehgal, K. ^{[7
]}

Bockorny, B. ^{[8
]}

Braiteh, F. ^{[9
]}

Peters, S. ^{[10
]}

Sanborn, R. E. ^{[11
]}

Zhou, P. ^{[12
]}

Nazarenko, N. ^{[13
]}

Patnaik, A. ^{[14
]}

机构：

[1] START Madrid Ctr Integral Oncol Clara Camp, Early Phase Clin Drug Dev Oncol, Madrid, Spain

[2] Inst Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France

[3] Case Western Reserve Univ, Case Comprehens Canc Ctr, Univ Hosp Seidman, Ctr Canc,Div Hematol & Oncol,Dept Med, Cleveland, OH 44106 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA

[5] Early Clin Drug Dev Grp, Vall Hebron Inst Oncol, Barcelona, Spain

[6] Royal Marsden Hosp, Phase Drug Dev Unit 1, London, England

[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[8] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA

[9] Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA

[10] Ctr Hosp Univ Vaudois CHUV, Dept Oncol, Lausanne, Switzerland

[11] Providence Canc Inst, Earle A Chiles Res Inst, Med Oncol, Portland, OR USA

[12] Seagen Inc, Biometr, Bothell, WA USA

[13] Seagen Inc, Early Stage Dev, Bothell, WA USA

[14] START San Antonio, Clin Res, San Antonio, TX USA

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.1077

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

555TiP

引用

页码：S613 / S613

页数：1